Item 8.01 Other Events
On April 22, 2021, Yumanity Therapeutics, Inc., issued a press release titled
"Yumanity Therapeutics' YTX-7739 Achieved Target Engagement at Doses That Were
Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy
Volunteers". A copy of the press release is attached hereto as Exhibit 99.1 and
is incorporated into this Item 8.01 by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit
No. Document
99.1 Yumanity Therapeutics, Inc. press release, dated April 22, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses